Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Amphastar Pharmaceuticals, Inc. on June 8, 2017. The company is incorporated in Delaware and is classified as an emerging growth company. The filing details the voting results for director elections and the ratification of the independent auditor.
Key Financial Metrics
This filing is a current report regarding corporate governance events and does not contain financial data. There are no disclosures regarding revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
No material financial changes are reported in this filing. The document solely addresses the outcomes of shareholder votes conducted at the Annual Meeting.
Guidance, Outlook, and Management Commentary
The filing contains no management commentary, financial guidance, outlook, risks, or contingencies. The primary content is the tabulation of votes for two proposals:
- Election of Directors: Three Class I directors (Jason B. Shandell, Richard Koo, and Floyd F. Petersen) were elected to serve until the 2020 annual meeting.
- Ratification of Auditor: Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2017.
Investor Verification Checklist
- Verify the specific vote counts for the three director nominees to assess shareholder support levels.
- Confirm the appointment of Ernst & Young LLP as the auditor for the 2017 fiscal year.
- Note that this filing does not provide financial performance data; refer to the most recent 10-Q or 10-K for financial metrics.